House com­mit­tee probes FTC dis­clo­sure of con­fi­den­tial in­fo in re­view­ing Am­gen-Hori­zon deal

House Over­sight Com­mit­tee Chair James Com­er (R-KY) sent a stern let­ter to FTC chair Lina Khan last week, claim­ing the com­mis­sion im­prop­er­ly dis­closed con­fi­den­tial in­for­ma­tion as it re­viewed the merg­er be­tween Am­gen and Hori­zon Ther­a­peu­tics, which was com­plet­ed in ear­ly Oc­to­ber.

Com­er al­leges that the FTC dis­closed con­fi­den­tial in­for­ma­tion pro­duced by Am­gen and Hori­zon on “at least four sep­a­rate oc­ca­sions” dur­ing the FTC’s in­ves­ti­ga­tion in­to the merg­er. The in­for­ma­tion in­clud­ed “in­ter­nal Hori­zon pre­sen­ta­tions, doc­u­ments, pre­dic­tions on FDA ap­proval, patent ex­pi­ra­tion dates, and re­search projects,” and was vis­i­ble to any­one who copied and past­ed the sec­tions from an elec­tron­ic copy of the doc­u­ment, he wrote in his let­ter dat­ed Nov. 20.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER